Resection of hepatic metastasis after 5-fluorouracil and cofactor for colon cancer.

Abstract

Hepatic metastases are common in colorectal cancer. However, only a small percentage of patients are candidates for resection. Neoadjuvant chemotherapy is used to downstage tumors so surgical resection becomes a viable option. We present a case of resection of hepatic metastasis from an 85-year-old patient with metastatic colorectal cancer after treatment with 5-Fluorouracil and 5,10-methylenetetrafolate (CoFactor), an analog of leucovorin, in a Phase II Clinical Trial. CoFactor was developed as a more active replacement of leucovorin to potentially allow reduced dosing of 5-FU. This could potentially be associated with diminished side effects. 5-Fluorouracil with leucovorin or CoFactor could represent another alternative for neoadjuvant chemotherapy prior to resection in metastatic colorectal cancer and warrants further studies, especially in elderly patients.

• Authors: Carrie L Costantini, Tony R Reid, Michael Bouvet
• Journal: Hepato-gastroenterology (Hepatogastroenterology) 2009 May-Jun Vol. 56 Issue 91-92 Pg. 645-9 ISSN: 0172-6390 [Print] Greece
• PMID: 19621672 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antimetabolites, Antineoplastic
• Vitamin B Complex
• Leucovorin
• Fluorouracil

Topics

• Adenocarcinoma (drug therapy, secondary, surgery)
• Aged, 80 and over
• Antimetabolites, Antineoplastic (therapeutic use)
• Colonic Neoplasms (drug therapy, pathology, surgery)
• Female
• Fluorouracil (therapeutic use)
• Hepatectomy
• Humans
• Leucovorin (analogs & derivatives, therapeutic use)
• Liver Neoplasms (drug therapy, secondary, surgery)
• Neoadjuvant Therapy
• Vitamin B Complex (therapeutic use)